金沙娱城乐377

金沙娱城乐377

中文

法规动态

当前位置: 首页 > 新闻动态 > 法规动态

Infliximab May Be Better Than Adalimumab For Ulcerative Colitis.

2013-10-16

MedPage today reports that research presented at the annual meeting of the American College of Gastroenterology suggests that “for patients with ulcerative colitis considering treatment with anti-tumor necrosis factor (TNF) therapy, infliximab (Remicade) may be a better choice than adalimumab (Humira).” Researchers found, “in a meta-analysis of studies that compared each of these anti-TNF agents with placebo,” that “odds ratios for remission after 8 weeks of induction therapy were 5.26 (95% CI 2.94-9.99) for infliximab and 2.22 (95% CI 1.23-3.98) for adalimumab.” Then, “using Bayesian random-effect indirect comparison meta-analysis, the” investigators “determined that the odds ratio for remission with adalimumab compared with infliximab was 0.42 (95% CI 0.17-0.97).”

上一篇:没有了

下一篇:没有了